Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Martin, Oeggerli"'
Autor:
Christian Ruiz, Stefan Kustermann, Elina Pietilae, Tatjana Vlajnic, Betty Baschiera, Leila Arabi, Thomas Lorber, Martin Oeggerli, Spasenija Savic, Ellen Obermann, Thomas Singer, Sacha I Rothschild, Alfred Zippelius, Adrian B Roth, Lukas Bubendorf
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0160807 (2016)
The use of patients' own cancer cells for in vitro selection of the most promising treatment is an attractive concept in personalized medicine. Human carcinoma cells from malignant pleural effusions (MPEs) are suited for this purpose since they have
Externí odkaz:
https://doaj.org/article/978afa43d8174d57b35ed16f87948089
Autor:
Martin Oeggerli, Yuemin Tian, Christian Ruiz, Barbara Wijker, Guido Sauter, Ellen Obermann, Uwe Güth, Inti Zlobec, Matthias Sausbier, Karl Kunzelmann, Lukas Bubendorf
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e41664 (2012)
KCNMA1 encodes the α-subunit of the large conductance, voltage and Ca(2+)-activated (BK) potassium channel and has been reported as a target gene of genomic amplification at 10q22 in prostate cancer. To investigate the prevalence of the amplificatio
Externí odkaz:
https://doaj.org/article/0ec1d421774e4a2db7de18cbffa9c12a
Autor:
Silvia Gluderer, Lukas Bubendorf, Susanna Stürm, Hugo Stocker, Mariacarla Andreozzi, Luigi Terracciano, George N. Thalmann, Edward P. Gelmann, Thomas C. Gasser, Martin Oeggerli, Christian Ruiz, Tobias Zellweger, Pasi A. Koivisto, Markus Germann, Andrew G. Glass, Marco G. Cecchini, Alexander Bachmann, Stephen Wyler, Cyrill A. Rentsch, Heikki Helin
Publikováno v:
The Prostate. 72:1678-1687
We recently established the rationale that NRBP1 (nuclear receptor binding protein 1) has a potential growth-promoting role in cell biology. NRBP1 interacts directly with TSC-22, a potential tumor suppressor gene that is differently expressed in pros
Autor:
Christian, Ruiz, Martin, Oeggerli, Markus, Germann, Silvia, Gluderer, Hugo, Stocker, Mariacarla, Andreozzi, George N, Thalmann, Marco G, Cecchini, Tobias, Zellweger, Susanna, Stürm, Pasi A, Koivisto, Heikki J, Helin, Edward P, Gelmann, Andrew G, Glass, Thomas C, Gasser, Luigi M, Terracciano, Alexander, Bachmann, Stephen, Wyler, Lukas, Bubendorf, Cyrill A, Rentsch
Publikováno v:
The Prostate
BACKGROUND We recently established the rationale that NRBP1 (nuclear receptor binding protein 1) has a potential growth promoting role in cell biology. NRBP1 interacts directly with TSC 22 a potential tumor suppressor gene that is differently express
Autor:
David R Holz, Tobias Zellweger, Martin Oeggerli, Spyro Mousses, Lukas Bubendorf, Heikki Helin, Pasi A. Koivisto, Irma M. Gonzales, Jeff Kiefer, Michael T. Barrett, Sandra Schneider, David O. Azorsa, Christian Ruiz, Alexander Bachmann
Publikováno v:
The Journal of Pathology. 223:543-552
Androgen withdrawal is the standard treatment for advanced prostate cancer. Although this therapy is initially effective, nearly all prostate cancers become refractory to it. Approximately 15% of these castration-resistant prostate cancers harbour a
Autor:
Tatjana Vlajnic, Spasenija Savic, Betty Baschiera, Stefan Kustermann, Elina Pietilae, Lukas Bubendorf, Thomas Singer, Alfred Zippelius, Martin Oeggerli, Leila Arabi, Ellen C. Obermann, Christian Ruiz, Adrian Roth, Thomas Lorber, Sacha I. Rothschild
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0160807 (2016)
PLoS ONE
PLoS ONE
Introduction The use of patients’ own cancer cells for in vitro selection of the most promising treatment is an attractive concept in personalized medicine. Human carcinoma cells from malignant pleural effusions (MPEs) are suited for this purpose s
Autor:
Matthias Sausbier, Inti Zlobec, Karl Kunzelmann, Lukas Bubendorf, Yuemin Tian, Uwe Güth, Barbara Wijker, Guido Sauter, Christian Ruiz, Martin Oeggerli, Ellen C. Obermann
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e41664 (2012)
PloS one
Oeggerli, Martin; Tian, Yuemin; Ruiz, Christian; Wijker, Barbara; Sauter, Guido; Obermann, Ellen; Güth, Uwe; Zlobec, Inti; Sausbier, Matthias; Kunzelmann, Karl; Bubendorf, Lukas (2012). Role of KCNMA1 in breast cancer. PLoS ONE, 7(8), e41664. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0041664
PLoS ONE
PloS one
Oeggerli, Martin; Tian, Yuemin; Ruiz, Christian; Wijker, Barbara; Sauter, Guido; Obermann, Ellen; Güth, Uwe; Zlobec, Inti; Sausbier, Matthias; Kunzelmann, Karl; Bubendorf, Lukas (2012). Role of KCNMA1 in breast cancer. PLoS ONE, 7(8), e41664. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0041664
PLoS ONE
KCNMA1 encodes the α-subunit of the large conductance, voltage and Ca(2+)-activated (BK) potassium channel and has been reported as a target gene of genomic amplification at 10q22 in prostate cancer. To investigate the prevalence of the amplificatio
Autor:
Christian, Ruiz, David R, Holz, Martin, Oeggerli, Sandra, Schneider, Irma M, Gonzales, Jeffrey M, Kiefer, Tobias, Zellweger, Alexander, Bachmann, Pasi A, Koivisto, Heikki J, Helin, Spyro, Mousses, Michael T, Barrett, David O, Azorsa, Lukas, Bubendorf
Publikováno v:
The Journal of pathology. 223(4)
Androgen withdrawal is the standard treatment for advanced prostate cancer. Although this therapy is initially effective, nearly all prostate cancers become refractory to it. Approximately 15% of these castration-resistant prostate cancers harbour a
Autor:
Ronald Simon, Hedvika Novotny, Michael Bloch, Peter Schraml, Guido Sauter, Martin Oeggerli, Martina Mirlacher, Christian Ruiz
Publikováno v:
Oncogene. 25(49)
Amplification of 6p22 occurs in about 10-20% of bladder cancers and is associated with enhanced tumour cell proliferation. Candidate target genes for the 6p22 amplicon include E2F3 and the adjacent gene NM_017774. To clarify which gene is representin
Autor:
Guido Sauter, Christian Ruiz, Michael J. Mihatsch, Ronald Simon, Boriana M. Zaharieva, Draga Toncheva, Martin Oeggerli, Thomas Gasser
Publikováno v:
International journal of cancer. 117(6)
Alterations of chromosome 8, preferentially deletions of 8p and gains of 8q, belong to the most frequent cytogenetic changes in bladder cancer. CMYC on 8q24 is a candidate oncogene in this region. Little is known about the clinical significance of CM